**Supplemental Table 1 Cardiac risk factors and echocardiographic characteristics by presence of thrombus/dense spontaneous echo contrast**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Apixaban-thrombus or dense SEC ( *n* = 15)** | **Apixaban - no thrombus or dense SEC (*n* = 211)** | ***P*-value** |
| Age | 66.7 ± 10.2 | 65.7 ± 11.9 | 0.726 |
| Race |  |  |  |
| White | 10 (66.7) | 180 (85.3) | 0.070 |
| Black | 5 (33.3) | 29 (13.7) | 0.006 |
| Hispanic | 0 (0) | 0 (0) | - |
| Asian | 0 (0) | 2 (0.9) | 1 |
| Most recent Cr | 1.09± 0.49 | 1.01 ± 0.32 | 0.558 |
| ESRD | 2 (13.3) | 4 (1.9) | 0.053 |
| Clopidogrel | 0 (0) | 7 (3.3) | 1 |
| Aspirin | 3 (0.2) | 80 (37.9) | 0.267 |
| CHA2DS2-VASc | 3.44 ± 1.24 | 2.84 ± 1.63 | 0.767 |
| CHF | 9 (60.0) | 69 (32.7) | 0.047 |
| Hypertension | 14 (93.3) | 170 (80.6) | 0.315 |
| Age > 75 | 3 (20.0) | 47 (22.3) | 1 |
| Diabetes | 2 (13.3) | 48 (22.7) | 0.531 |
| Stroke | 0 (0) | 11 (5.2) | 1 |
| Vascular disease | 1 (6.7) | 25 (11.8) | 1 |
| Age > 65 | 11 (3.3) | 134 (63.5) | 0.582 |
| Female | 8 (53.3) | 79 (37.4) | 0.274 |
| Persistent AF | 8 (53.3) | 51 (24.2) | 0.028 |
| **Echocardiographic data** | | | |
| LVEF | 38.3 ± 17.8 | 48.5 ± 13.8 | 0.047 |
| LVEF < 30 | 6 (40.0) | 27 (12.8) | 0.012 |
| LVEF 30-49 | 3 (20.0) | 41 (19.4) | 1 |
| LVEF ≥ 50 | 6 (40.0) | 143 (67.8) | 0.045 |
| LAA velocity | 25.8 ± 10.2 | 49.9± 17.5 | < 0.001 |
| LAA velocity < 40 cm/s | 13 (86.7) | 58 (37.5) | < 0.001 |
| LA dilation |  |  |  |
| Moderate | 2 (13.3) | 64 (30.3) | 0.241 |
| Severe | 11 (73.3) | 48 (22.7) | <0.001 |
| Mitral Regurgitation |  |  |  |
| Moderate | 4 (26.7) | 49 (23.2) | 0.757 |
| Severe | 1 (6.7) | 4 (1.9) | 0.294 |

AF: Atrial fibrillation; CHF: Congestive heart failure; Cr: Creatinine; ESRD: End-stage renal disease; LA: Left atria; LAA: Left atrial appendage; LVEF: Left ventricular ejection fraction; SEC: Spontaneous echo contrast.

**Supplemental Table 2 Prevalence of left atrial appendage thrombus by CHA2DS2-VASc score**

|  |  |
| --- | --- |
| **CHA2DS2-VASc score** | **Apixaban** |
| 0 | 0/20 (0%) |
| 1 | 0/25 (0%) |
| 2 | 3/54 (5.6%) |
| 3 | 0/51 (0%) |
| 4 | 2/41 (4.9%) |
| 5 | 2/23 (8.7%) |
| 6 | 0/9 (0%) |
| 7 | 0/3 (0%) |

**Supplemental Table 3 Univariate and multivariate predictors of left atrial appendage thrombus or dense spontaneous echo contrast**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Apixaban** | | | | | | |
| **Variable** | **Unadjusted (univariate analysis)** | | | **Adjusted (multivariate analysis)** | | |
|  | OR | 95%CI | *P*-value | OR | 95%CI | *P*-value |
| CHF | 1.959 | 0.55-6.98 | 0.2999 |  |  |  |
| Hypertension | 2.703 | 0.34-21.51 | 0.3474 |  |  |  |
| Age > 65 | 1.319 | 0.33-5.25 | 0.6944 |  |  |  |
| Age > 75 | 0.379 | 0.05-3.06 | 0.3625 |  |  |  |
| Diabetes | 0.875 | 0.18-4.26 | 0.8686 |  |  |  |
| Stroke | 1.561 | 0.19-13.11 | 0.6819 |  |  |  |
| Vascular disease | 0.849 | 0.10-6.99 | 0.8789 |  |  |  |
| CHA2DS2-VASc | 1.112 | 0.75-1.64 | 0.5918 |  |  |  |
| Gender (female) | 1.068 | 0.29-3.90 | 0.9203 |  |  |  |
| Persistent AF | 4.613 | 1.25-16.97 | **0.02141** | 4.665 | 0.81-27.0 | 0.0856 |
| LVEF < 30% | 6.714 | 1.83-24.68 | **0.00411** | 1.209 | 0.21-6.76 | 0.8294 |
| LVEF < 50% | 4.867 | 1.22-19.39 | **0.02482** |  |  |  |
| Severe left atrial dilation | 13.190 | 1.84-94.30 | **0.01021** | 5.915 | 0.74-46.98 | 0.0927 |
| LAA velocity (decrease) | 1.162 | 1.075-1.25 | **0.00011** | 1.131 | 1.031-1.235 | **0.0061** |
| LAA velocity < 40 cm/s | 22.355 | 2.77-180.12 | **0.00352** |  |  |  |

**1**Significant factor in the univariate model which is used in the multivariate model; **2**Significant factor in the univariate model but not considered in the multivariate model. AF: Atrial fibrillation; CHF: Congestive heart failure; CI: Confidence interval; LAA: Left atrial appendage; LVEF: Left ventricular ejection fraction; OR: Odds ratio.